

Non-Alcoholic SteatoHepatitis (NASH) Market To Reach USD 180.09 Billion By 2028, CAGR of 58.64% | Reports And Data

Increasing prevalence of obesity coupled with rising adoption of sedentary lifestyle is the major factor influencing market growth.

NEW YORK, NY, UNITED STATES,
November 2, 2021 /EINPresswire.com/

-- The global [Non-alcoholic Steatohepatitis \(NASH\) market](#) is expected to reach USD 180.09 Billion

by 2028, according to a new report by Reports and Data. This can be mainly associated with increasing consumption of fats globally. Based on statistics, Nonalcoholic Fatty Liver Disease (NAFLD) affects around 80 million to 100 million Americans. NAFLD is expected to become the most common chronic liver condition globally in relation to the obesity and type 2 diabetes in the coming years. Estimates suggest that the incidence of NASH is projected to witness an increase of around 63% between 2015 and 2030.

Increase in the number of expected launch of pipeline drugs is also a significant factor stimulating market demand. The current statistics for the U.S. suggest that the healthcare cost associated with NASH is around USD 5 billion. Since the incidence of NASH is projected to rise significantly, estimates suggest that, if unchecked, the healthcare costs associated with NASH could rise up to USD 18 billion by 2030. Companies around the world have been focusing on bringing out new drugs in the market for the treatment of the disease.

North America is expected to be a key revenue generating region in the forecast period. The market is projected to grow at a CAGR of 53% in the forecast period. Increasing incidence of disease in the region has created a growth opportunity for the drug makers. Manufacturers have been focusing on bringing out new drugs. For instance: Recently in November 2019, Gilead Sciences, Inc. unveiled that its drug Selonsertib which is a dual anti-apoptotic and anti-inflammatory drug is currently undergoing Phase-3 trials for NASH compensated cirrhosis and NASH fibrosis.

To Gain Access to an all-inclusive PDF Sample Report, Click Here:



Reports And Data

<https://www.reportsanddata.com/sample-enquiry-form/1111>

Leading companies operating in the market and profiled in the report include:

Genfit, Intercept Pharmaceuticals, Gilead Sciences, Galmed Pharmaceuticals, Inventiva, Allergan and Tobira Therapeutics. Gilead Sciences is a key player in the NASH market. With a global presence in more than 35 countries, the company offers drugs including Selonsertib, Cilofexor and Firsocostat for the treatment of NASH.

Market Overview:

The pharmaceutical and healthcare sector is rapidly expanding in terms of revenue in the recent years and is expected to register robust CAGR over the forecast period of 2028. Factors such as rapid advancements in the pharma and healthcare sector, adoption of latest technologies, tools and equipment, emergence of various new diseases and improvements in healthcare facilities and infrastructure. In addition, rising healthcare expenditure, increasing per capita income in the developing countries and favorable reimbursement policies are fueling market growth. Increasing funds by various public and private sectors and increasing investments to develop enhanced products and devices are also boosting market growth. Moreover, increasing preference for ambulatory services and point of care services, and increasing funds for research centers and hospitals for drug discovery is expected to fuel market growth going ahead.

Competitive Landscape:

The report provides details about competitive landscape of global Non-Alcoholic Steatohepatitis (NASH) market focusing on every market player, its global position, revenue generation product portfolio, company overview, financial planning and business expansion plans. The global Non-Alcoholic Steatohepatitis (NASH) market is quite competitive and comprises various key players at global and regional levels. Key players are investing in research and development activities, and strategizing various plans such as mergers and acquisitions, partnerships, joint ventures, new product launches, to enhance their product base and strengthen their market position.

Grab Your Report at an Impressive Discount! Please Click Here:

<https://www.reportsanddata.com/discount-enquiry-form/1111>

Further key findings from the report suggest

- Elafibranor is projected to be one of the fastest growing drugs of the NASH market. The segment is projected to grow at a CAGR of 55.4% in the forecast period. The drug which is an oral treatment is GENFIT's lead pipeline product. It has been positioned as a first-in-class drug to treat NASH. The drug is currently being evaluated in the clinical Phase 3 study RESOLVE-IT.
- North American market is forecasted to grow at a CAGR of 53% in the coming years. The

disease is considered to be one of the leading causes of cirrhosis in adults in the U.S. High incidence of diabetes and obesity in the region are considered to be the main reason behind increasing incidence of NASH. Based on American Liver Foundation's National Medical Advisory Committee currently around 30 million Americans have been diagnosed with NASH. Additionally, around 90% of the NASH patients suffer from either obesity or diabetes.

To know more about the report @ <https://www.reportsanddata.com/report-detail/non-alcoholic-steatohepatitis-nash-market>

For the purpose of this report, Reports and Data have segmented global NASH market on the basis of disease cause, drug type, end-user and region:

Disease Cause Outlook (Revenue, USD Million; 2018-2028)

- Hypertension
- Heart Disease
- High Blood Lipid
- Type 2 Diabetes
- Obesity

Drug Type Outlook (Revenue, USD Million; 2018-2028)

- Vitamin E & Pioglitazone
- Ocaliva
- Elafibranor
- Selonsertib
- Cenicriviroc
- Others

End-user Outlook (Revenue, USD Million; 2018-2028)

- Hospitals
- Clinics
- Homecare settings

Regional Outlook:

- North America (U.S., Canada, Mexico)
- Europe (Germany, U.K., Italy, France, BENELUX, Rest of Europe)
- Asia Pacific (China, India, Japan, South Korea, Rest of APAC)
- Latin America (Brazil, Rest of LATAM)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)

Request a customization of the report @ <https://www.reportsanddata.com/request-customization-form/1111>

Thank you for reading the research report. We also provide report customization as per client request. Kindly contact us to know more about this customization feature and our team will offer you with the best suited report.

Browse More Reports:

Kidney Function Tests Market @ <https://www.medgadget.com/2021/10/kidney-function-tests-market-growth-driven-by-surging-prevalence-of-chronic-kidney-diseases-reports-and-data.html>

Radiotherapy Market @ <https://www.medgadget.com/2021/10/increasing-use-of-radiotherapy-to-treat-some-cancers-and-as-a-palliative-treatment-to-drive-revenue-growth-of-radiotherapy-market-reports-and-data.html>

Aneurysm Clips Market @ <https://www.medgadget.com/2021/10/aneurysm-clips-market-growth-driven-by-rising-demand-for-the-surgical-procedures-worldwide-reports-and-data.html>

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client's make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

Tushar Rajput
Reports and Data
+18008193052 ext.
[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/555344512>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire,

Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.